Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive crawled date : 2021 - 06 - 28 save search
Medtronic InPen™ Real-World Data and Extended Infusion Set* Pivotal Trial Results Demonstrate Strong Clinical Outcomes and Positive User Experience
Published: 2021-06-28 (Crawled : 17:00) - biospace.com/
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: 0.29%
H: 0.1%
C: -1.24%
positive trial trial results
Eiger BioPharmaceuticals Announces Presentation of Positive Phase 2 Results of Avexitide in Congenital Hyperinsulinism at the American Diabetes Association Virtual 81st Scientific Session
Published: 2021-06-28 (Crawled : 16:00) - biospace.com/
EIGR | $1.725 -1.45% 140K
|
Health Technology
|
| O: 4.84%
H: 5.28%
C: -1.65%
presentation diabetes phase 2 biopharma positive phase 2 results results insulin
MYM’s Acquisition by IMCC Receives Positive Recommendations from leading Independent Proxy Advisory Firms
Published: 2021-06-28 (Crawled : 14:00) - globenewswire.com
IMCC | $0.611 -15.93% -18.95% 600K
|
Manufacturing
|
| O: 2.56%
H: 3.27%
C: 3.27%
acquisition positive
Daré Bioscience Announces Positive Phase 1 Results for DARE-HRT1
Published: 2021-06-28 (Crawled : 12:15) - globenewswire.com
DARE | $0.2838 -3.83% -3.98% 550K
|
Health Technology
|
| O: 0.0%
H: 1.78%
C: -0.59%
phase 1 positive results phase 2 phase 3 bioscience
Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis
Published: 2021-06-28 (Crawled : 12:00) - ir.hoththerapeutics.com
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 1.26%
H: 4.97%
C: -1.86%
treatment phase 1 positive results dermatitis trial atopic dermatitis phase 1b al001 adi-001 phase 2b
Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism
Published: 2021-06-28 (Crawled : 10:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.34%
H: 0.47%
C: 0.24%
KYMR | $33.965 -3.29% -3.4% 630K
|
Health Technology
|
| O: 2.97%
H: 3.46%
C: 3.24%
phase 1 positive results trial phase 2
Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial
Published: 2021-06-28 (Crawled : 08:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.34%
H: 0.47%
C: 0.24%
phase 2 phase 2/3 positive results topline trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.